ArticleJACC. Case reports2026
Trabectedin-Associated Myocardial Infarction With Nonobstructive Coronary Arteries.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrabectedin is a marine-derived alkylating agent used to treat soft tissue sarcomas. CASE SUMMARY: We present a case of myocardial infarction with nonobstructive coronary arteries (MINOCA) in a 58-year-old man with no prior cardiac history who was receiving trabectedin for metastatic liposarcoma. Initial work-up revealed elevated high-sensitivity troponin, unremarkable electrocardiogram and echocardiogram, and mild nonobstructive coronary disease on coronary angiography. The patient's chest discomfort recurred days after another chemotherapy cycle, and it was hypothesized that coronary vasospasm produced his symptoms. Prophylactic amlodipine and isosorbide mononitrate were administered around subsequent cycles, with complete resolution of symptoms. DISCUSSION: Recurrent episodes of acute coronary syndrome after trabectedin infusions that resolved with vasodilator pretreatment supported trabectedin-induced coronary vasospasm as the mechanism of MINOCA in this patient. This is to our knowledge the first reported such case with trabectedin. TAKE-HOME MESSAGE: Patients who develop trabectedin-associated MINOCA may benefit from pretreatment with anti-vasospastic antianginals to allow for safe continuation of therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.